JP4486817B2 - １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 - Google Patents

１，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 Download PDF

Info

Publication number
JP4486817B2
JP4486817B2 JP2003554646A JP2003554646A JP4486817B2 JP 4486817 B2 JP4486817 B2 JP 4486817B2 JP 2003554646 A JP2003554646 A JP 2003554646A JP 2003554646 A JP2003554646 A JP 2003554646A JP 4486817 B2 JP4486817 B2 JP 4486817B2
Authority
JP
Japan
Prior art keywords
compound
general formula
amino
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003554646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517666A (ja
JP2005517666A5 (enExample
Inventor
ハイケ・ギーレン
フォルクハルト・ミン−ジャン・リ
ウルリッヒ・ローゼントレター
カール−ハインツ・シュレンマー
スヴェン・アラーハイリゲン
ケビン・ナッシュ
メアリー・フィッツジェラルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130553A external-priority patent/GB2383326A/en
Priority claimed from GB0216664A external-priority patent/GB2390849A/en
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2005517666A publication Critical patent/JP2005517666A/ja
Publication of JP2005517666A5 publication Critical patent/JP2005517666A5/ja
Application granted granted Critical
Publication of JP4486817B2 publication Critical patent/JP4486817B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003554646A 2001-12-20 2002-12-09 １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 Expired - Fee Related JP4486817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0130553A GB2383326A (en) 2001-12-20 2001-12-20 Antiinflammatory dihydropyridines
GB0216664A GB2390849A (en) 2002-07-17 2002-07-17 3-Acyl-1,4-dihydro-1,4-di(phenyl/azinyl/diazinyl)pyridine derivatives for use as human neutrophil elastase inhibitors
PCT/EP2002/013931 WO2003053930A1 (en) 2001-12-20 2002-12-09 1,4-dihydro-1,4-diphenylpyridine derivatives

Publications (3)

Publication Number Publication Date
JP2005517666A JP2005517666A (ja) 2005-06-16
JP2005517666A5 JP2005517666A5 (enExample) 2006-02-02
JP4486817B2 true JP4486817B2 (ja) 2010-06-23

Family

ID=26246892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554646A Expired - Fee Related JP4486817B2 (ja) 2001-12-20 2002-12-09 １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体

Country Status (8)

Country Link
US (1) US7199136B2 (enExample)
EP (1) EP1458682B1 (enExample)
JP (1) JP4486817B2 (enExample)
AU (1) AU2002361992A1 (enExample)
CA (1) CA2470813A1 (enExample)
DE (1) DE60214428T2 (enExample)
ES (1) ES2271365T3 (enExample)
WO (1) WO2003053930A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
AU2003255492A1 (en) * 2002-09-10 2004-04-30 Bayer Healthcare Ag Heterocyclic derivatives
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CA2556463C (en) * 2004-02-19 2012-08-14 Bayer Healthcare Ag Dihydropyridinone derivatives
JP4825194B2 (ja) * 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
EP1730121B1 (en) 2004-02-26 2013-08-07 Bayer Intellectual Property GmbH 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
DE102009004197A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
AU2010215261A1 (en) 2009-02-17 2011-09-08 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 MAP kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
CN103974953B (zh) 2011-12-09 2016-06-29 奇斯药制品公司 激酶抑制剂
CN103987708B (zh) 2011-12-09 2016-06-22 奇斯药制品公司 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途
CN105968110B (zh) 2011-12-09 2018-04-27 奇斯药制品公司 激酶抑制剂
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) * 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9958484B2 (en) * 2015-07-08 2018-05-01 Qualcomm Incorporated Apparatus and method for measuring load current by applying compensated gain to voltage derived from drain-to-source voltage of power gating device
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3394060A1 (en) 2015-12-23 2018-10-31 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
CN109890817B (zh) 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
JP2020015705A (ja) * 2018-07-27 2020-01-30 住友化学株式会社 アニリン化合物の製造方法
MA56518A (fr) 2019-06-18 2022-04-27 Hoffmann La Roche Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
JP7716993B2 (ja) 2019-06-18 2025-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2753946A1 (de) * 1977-12-03 1979-06-13 Bayer Ag 1-n-aryl-1,4-dihydropyridine und ihre verwendung als arzneimittel
DE3222367A1 (de) 1982-06-15 1983-12-15 Bayer Ag, 5090 Leverkusen Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
DE4328884A1 (de) 1993-08-27 1995-03-02 Bayer Ag Verwendung von N-alkylierten 1,4-Dihydropyridincarbonsäureestern als Arzneimittel
JP3337829B2 (ja) * 1994-07-29 2002-10-28 日研化学株式会社 １，４−ジヒドロピリジン化合物

Also Published As

Publication number Publication date
CA2470813A1 (en) 2003-07-03
DE60214428T2 (de) 2007-09-20
US7199136B2 (en) 2007-04-03
ES2271365T3 (es) 2007-04-16
JP2005517666A (ja) 2005-06-16
AU2002361992A1 (en) 2003-07-09
EP1458682A1 (en) 2004-09-22
US20050165014A1 (en) 2005-07-28
DE60214428D1 (de) 2006-10-12
WO2003053930A1 (en) 2003-07-03
EP1458682B1 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
JP4486817B2 (ja) １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体
JP5134248B2 (ja) ジヒドロピリジノン誘導体
Atwal et al. Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1, 4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines
EP1546113B1 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
US7981892B2 (en) Disubstituted phthalazine hedgehog pathway antagonists
JP4708034B2 (ja) 急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体
SK284665B6 (sk) Heterocyklické deriváty inhibujúce faktor Xa, farmaceutický prostriedok s ich obsahom, spôsob ich prípravy a ich použitie
JP2008514703A (ja) 置換２ｈ−１，３−ベンゾオキサジン−４（３ｈ）−オン
BRPI0721451A2 (pt) Compostos de 4-piperidiniluréia como inibidores de epóxido hidrolase solúvel
SK1272000A3 (en) Heterocyclic derivatives which inhibit factor xa
WO1999033805A1 (en) Aromatic compounds having cyclic amino or salts thereof
CN117756789A (zh) 作为选择性Janus激酶抑制剂的氨基吡唑类化合物
KR20040104503A (ko) 니트로소디페닐아민 유도체 및 산화성 스트레스 병변에대한 이의 약제학적 용도
HUP0400819A2 (hu) 4-(Bifenil-karbonil-amino)-piperidin-származékok, mint MTP inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
KR20110011712A (ko) 신규한 화합물 ｖｉｉ
GB2383326A (en) Antiinflammatory dihydropyridines
KR20100097725A (ko) 신규 화합물 ⅲ
ES2372306T3 (es) 4-cromenonil-1,4-dihidropiridincarbonitrilos y su uso.
CZ20012867A3 (cs) Heterocyklické deriváty jako inhibitory faktoru Xa a farmaceutická kompozice, která je obsahuje
KR20100097701A (ko) 비만 치료제로서의 모르폴린 유도체
KR20110015446A (ko) 렙틴 수용체 조절제 유사체로서의 신규한 피리딘 유도체
CA2361636A1 (en) Use of pyrazole carboxamides
JP4708025B2 (ja) ヘテロ環誘導体
EP0370821B1 (en) 1,4-dihydropyridine derivatives
JP4163260B2 (ja) １，４−ジヒドロピリジン誘導体および治療におけるその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091021

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20091021

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100329

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130402

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees